COVID-19: NTUH gets green light for Moderna-Medigen trial taipeitimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from taipeitimes.com Daily Mail and Mail on Sunday newspapers.
Medigen to begin phase 2 vaccine candidate trials
By Kao Shih-ching / Staff reporter
Medigen Vaccine Biologics Corp (高端疫苗) on Wednesday said it plans to begin phase 2 clinical trials next week for its COVID-19 vaccine candidate and expects to apply by the end of June for emergency use authorization for the drug.
The company has started recruiting participants after last week obtaining Food and Drug Administration (FDA) permission to launch the phase 2 trials.
The company plans to recruit 3,700 participants, the most ever in such trials in Taiwan, as it aims to effectively examine the efficacy of its vaccine over the next three months, it said.
Researchers at Medigen Vaccine Biologics Corp. CNA photo Aug. 30, 2020
Taipei, Jan. 6 (CNA) Medigen Vaccine Biologics Corp. (MVC), a Taiwanese company whose COVID-19 vaccine candidate has been approved for second-stage clinical trials, said Wednesday that it will recruit 3,700 volunteers to participate in the trials over the next three months.
The company is partnering with 11 hospitals in Taiwan to speed up the process, with the hope of applying for emergency use authorization (EUA) for the vaccine in the second quarter of the year, said Lin Tzou-yien (林奏延), chairman of the National Health Research Institutes and chief convener of the trials.
The vaccine, called MVC-COV1901, was jointly developed by the United States National Institutes of Health (NIH) and Medigen, said Hsieh Szu-min (謝思民), the principal investigator of the trials.